Insiders See US$5.84m Investment In Summit Therapeutics Jump Last Week
Insiders See US$5.84m Investment In Summit Therapeutics Jump Last Week
Summit Therapeutics Inc. (NASDAQ:SMMT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 18% resulting in a US$920m addition to the company's market value. As a result, the stock they originally bought for US$5.84m is now worth US$27.5m.
在過去12個月內購買Summit Therapeutics Inc. (NASDAQ:SMMT)股票的內部人士上週受到了豐厚的回報。該股票上漲了18%,使得公司市值增加了9200萬美元。因此,他們最初以584萬美元購買的股票現在價值2750萬美元。
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
雖然我們認爲股東不應僅僅跟隨內部人士的交易,但邏輯告訴我們,應該注意內部人士是購買還是出售股票。
Summit Therapeutics Insider Transactions Over The Last Year
過去一年內的Summit Therapeutics內部交易情況。
Over the last year, we can see that the biggest insider purchase was by COO, CFO & Director Manmeet Soni for US$5.0m worth of shares, at about US$1.68 per share. We do like to see buying, but this purchase was made at well below the current price of US$8.55. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
過去一年內最大的內部購買者是COO、CFO和董事Manmeet Soni,購買了價值500萬美元的股票,每股價格約爲1.68美元。我們希望看到購買,但是這次購買價格遠低於當前的8.55美元。雖然這表明內部人士認爲低價時股票被低估了,但這次交易並不能告訴我們他們對當前價格的看法。
While Summit Therapeutics insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
過去一年,Summit Therapeutics內部人士購買了股票,但他們沒有出售。您可以在下圖中看到過去一年的內部交易情況(按公司和個人分類)。如果單擊圖表,您可以查看所有單個交易,包括股票價格、個人和日期!
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240714/0-d5290eae984308c5f3212f6ad55f3280-0-28afb10fe216ef259f7e8434975d3506.png/big)
Summit Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Summit Therapeutics不是唯一一隻內部人士在購買的股票。因此,請查看此免費的低調公司內部購買清單。
Insider Ownership Of Summit Therapeutics
Summit Therapeutics內部所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Summit Therapeutics insiders own 84% of the company, worth about US$5.0b. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
對於普通股東來說,值得檢查公司內部人員持有的股份數量。通常情況下,內部人員持股越高,就越有可能激勵他們爲長期建設公司。很高興看到Summit Therapeutics內部人員擁有公司的84%,價值約50億美元。內部人員的這種重要持股通常會增加公司爲所有股東的利益而運營的機會。
What Might The Insider Transactions At Summit Therapeutics Tell Us?
Summit Therapeutics內部交易可能告訴我們什麼?
The fact that there have been no Summit Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like Summit Therapeutics insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 3 warning signs with Summit Therapeutics and understanding them should be part of your investment process.
最近沒有發生過Summit Therapeutics內部交易的事實當然不會讓我們煩惱。更好的是,過去一年的交易是令人鼓舞的。更多內部人士購買當然是很好的,但總的來說,Summit Therapeutics內部人士持有公司的大量股份,並對未來持樂觀態度。因此,雖然了解內部人員在買賣上的動向很有幫助,但了解特定公司面臨的風險也同樣重要。在投資風險方面,我們已經確定了幾個警示信號,並且了解它們應該是投資過程的一部分。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。